


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

in which

each of A,B,D and E is independently C-R¹;

X is carbon;

Y is N;

Z is oxygen, sulphur, a C₁₋₆alkylene chain or a bond;

R¹ is independently selected from hydrogen, halogen, CN, nitro, S(O)_xR⁶, OR⁶, SO₂NR⁴R⁵, CONR⁴R⁵, NR⁴R⁵, NR⁷SO₂R⁷, NR⁷C(O)_xR⁷, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁₋₆alkyl, and aryl,

the latter four groups being optionally substituted by one or more substituents independently selected from 1-3 halogen atoms, -OR⁷ and -NR⁴R⁵, S(O)xR⁸, C(O)NR⁴R⁵, where x is 0,1 or 2;

R³ is a quinoline group, which is optionally substituted by one or more substituents independently selected from halogen, CN, nitro, S(O)xR⁶, OR⁷, SO₂NR⁴R⁵, CONR⁴R⁵, NR⁴R⁵, NR⁷SO₂R³, NR⁷C(O)xR⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁₋₆ alkyl, the latter three groups being optionally substituted by one or more substituents independently selected from halogen atoms, -OR⁶ and -NR⁴R⁵, where x= 0,1 or 2;

R⁴ and R⁵ independently represent a hydrogen atom, a C₁₋₆alkyl group, or aryl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, aryl, -OR¹² and -NR¹³R¹⁴, -CONR¹³R¹⁴, -NR¹³COR¹⁴, -SO₂NR¹³R¹⁴, NR¹³SO₂R¹⁴;

R⁶ represents a C₁₋₆alkyl which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, -OR⁹ and -NR¹⁰R¹¹,

each of R⁷, R⁸ R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, independently represents a hydrogen atom, C₁-C₆, alkyl, or an aryl or a heteroaryl group which may be optionally substituted by one or more halogen atoms, OH, O-C₁-C₆alkyl; and

R¹⁵ is hydrogen, C₁₋₄ alkyl, -COC₁-C₄ alkyl, -COQC₁-C₄alkyl, Q=O or NR⁶.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Previously Presented) A compound according to claim 1 in which Z is a bond.
6. (Cancelled)
7. (Cancelled)
8. (Previously Presented) A compound according to claim 1 in which Z is sulfur, methylene or a bond.
9. (Currently Amended) A compound according to claim 1 selected from: 5-methyl-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid; 5-cyano-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid; 3-(6-fluoro-4-quinolinyl)-4-(trifluoromethyl)-1*H*-indazole-1-acetic acid; and 4-iodo-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid; or a pharmaceutically acceptable salt thereof.
10. (Cancelled)
11. (Withdrawn) A method of treating a disease mediated by prostaglandin D2, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claim 1.
12. (Withdrawn) A method of treating according to claim 11 wherein the disease is asthma or rhinitis.
13. (Cancelled)

14. (Cancelled)

15. (Withdrawn-amended) The method according to claim 11 wherein the compound is selected from:

5-methyl-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

5-cyano-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

3-(6-fluoro-4-quinolinyl)-4-(trifluoromethyl)-1*H*-indazole-1-acetic acid; and

4-iodo-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

or a and pharmaceutically acceptable salt salts thereof.